ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Development of resistance to TKIs in CML has been assigned to Bcr‐Abl‐dependent and ‐independent mechanisms, and mutations of the ABL1 kinase domain are the most general cause of resistance (Rostami et al., 2015).